Clene Soon Will Complete Phase 2 Trial Testing CNM-Au8

Clene Soon Will Complete Phase 2 Trial Testing CNM-Au8

305911

Clene Soon Will Complete Phase 2 Trial Testing CNM-Au8

The last patient visit has been completed in Clene’s Phase 2 trial investigating the potential of CNM-Au8 — which uses nanotechnology to prevent the loss of motor neurons — for the treatment of amyotrophic lateral sclerosis (ALS). A total of 45 people with the neurological disorder had been enrolled in the Australia-based RESCUE-ALS trial (NCT04098406), and all necessary procedures for its closure are now underway, according to Clene. Topline data is expected in the next couple…

You must be logged in to read/download the full post.